Acute pyelonephritis in adults: Prediction of mortality and failure of treatment

Archives of Internal Medicine

Volumn 163, Issue 10, 2003, Pages 1206-1212

  Efstathiou, Stamatis P ^a   Pefanis, Angelos V ^a   Tsioulos, Dimitrios I ^a   Zacharos, Ioannis D ^a   Tsiakou, Aphrodite G ^a   Mitromaras, Athanasios G ^a   Mastorantonakis, Stylianos E ^a   Kanavaki, Sophie N ^b   Mountokalakis, Theodore D ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; IMMUNOSUPPRESSIVE AGENT; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TEICOPLANIN; TICARCILLIN; TIMENTIN; VANCOMYCIN;

ACUTE PYELONEPHRITIS; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CATHETERIZATION; DIABETES MELLITUS; FEMALE; GENDER; HEALTH STATUS; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPTIC SHOCK; TREATMENT FAILURE; URINE CULTURE;

ADULT; AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, MICROBIAL; FEMALE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PYELONEPHRITIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT FAILURE;

EID: 0038582460     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.10.1206     Document Type: Review

References (48)

1. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001;183(suppl 1):S1-S4.
2. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women: Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999;29:745-758.
3. Stamm WE. Urinary tract infections. In: Root RK, Waldvogel F, Corey L, Stamm WE, eds. Clinical Infectious Diseases: A Practical Approach. New York, NY: Oxford University Press Inc; 1999:649-656.
4. Ispahani P, Pearson NJ, Greenwood D. An analysis of community and hospital-acquired bactaeremia in a large teaching hospital in the United Kingdom. Q J Med. 1987;63:427-440.
5. Roberts FJ, Geere IW, Coldman A. A three-year study of positive blood cultures, with emphasis on prognosis. Rev Infect Dis. 1991;13:34-46.
6. Schaeffer AJ. Urinary tract infections: antimicrobial resistance. Curr Opin Urol. 2000;10:23-24.
7. Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 1992;257:1050-1055.
8. Leibovici L, Greenshtain S, Cohen O, Wysenbeek AJ. Toward improved empiric management of moderate to severe urinary tract infections. Arch Intern Med. 1992;152:2481-2486.
9. Svanborg C. Resistance to urinary tract infection. N Engl J Med. 1993;329:802-803.
10. Dyer IE, Sankary TM, Dawson JA. Antibiotic resistance in bacterial urinary tract infections, 1991 to 1997. West J Med. 1998;169:265-268.
11. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis. 2001;33:89-94.
12. Lipsky BA. Urinary tract infections in men: epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med. 1989;110:138-150.
13. Schaeffer AJ. Urinary tract infection in men - state of the art. Infection. 1994; 22(suppl 1):S19-S21.
14. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection: Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992;15(suppl 1):S216-S227.
15. Hofer M. Ultrasound Teaching Manual. New York, NY: Thieme-Stratton Inc; 1999.
16. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard. 5th ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993. NCCLS document M2-A5.
17. SPSS Inc. Statistical Package for the Social Sciences. Chicago, Ill: SPSS Inc; 2000. Windows version, release 10.0.
18. Sadek Sabbour M, Abd-el-Hamid T, Hussein SK. Infection in immunosuppressed patients. Chemioterapia. 1984;3:19-24.
19. Nicolle LE. Urinary tract pathogens in complicated infection and in elderly individuals. J Infect Dis. 2001;183(suppl 1):S5-S8.
20. Gilstrap LC III, Ramin SM. Urinary tract infections during pregnancy. Obstet Gynecol Clin North Am. 2001;28:581-591.
21. Ronald A, Ludwig E. Urinary tract infections in adults with diabetes. Int J Antimicrob Agents. 2001;17:287-292.
22. Vatopoulos AC, Kalapothaki V, Legakis NJ, for the Greek Network for the Surveillance of Antimicrobial Resistance. An electronic network for the surveillance of antimicrobial resistance in bacterial nosocomial isolates in Greece. Bull World Health Organ. 1999;77:595-601.
23. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis. 2001;33:615-621.
24. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-aquired urinary tract infections. Ann Intem Med. 2001;135:41-50.
25. Bemer-Melchior P, Gilly L, Jugroot-Klotz K, Brun T, Nevot P, Paul G. Resistance to amoxicillin and amoxicillin-clavulanic acid combination of 231 clinical strains of Escherichia coli, isolated in 1992 at the Cochin Hospital [in French]. Pathol Biol (Paris). 1995;43:760-765.
26. Vanak D, Sauvaget C, Muller-Serieys C, Millot G, Bergogne-Berezin E. β-Lactamase producing Escherichia coli, in vitro susceptibility of clinical strains to β-lactamase inhibitors. In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; Washington, DC; 1983. Washington, DC: American Society for Microbiology; 1983:143. Abstract 132.
27. Henquell C, Sirot D, Chanal C, et al. Frequency of inhibitor-resistant TEM β-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother. 1994;34:707-714.
28. World Health Organization. Report on Infectious Diseases: Removing Obstacles to Healthy Development. Geneva, Switzerland; World Health Organization; 1999.
29. Kahlmeter G. The ECO.SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens: interim report. J Antimicrob Chemother. 2000;46(suppl 1):15-22.
30. Vatopoulos AC, Kalapothaki V, Legakis NJ, for the Greek Network for the Surveillance of Antimicrobial Resistance. Bacterial resistance to ciprofloxacin in Greece: results from the National Electronic Surveillance System. Emerg Infect Dis. 1999; 5:471-476.
31. Legakis NJ, Tzouvelekis LS, Tsakris A, Legakis JN, Vatopoulos AC. On the incidence of antibiotic resistance among aerobic gram-negative rods isolated in Greek hospitals. J Hosp Infect. 1993;24:233-237.
32. Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents. 2001;18:211-215.
33. Giamarellou H. Fleroxacin in complicated urinary tract infections. Chemotherapy. 1996;42(suppl 1):17-27.
34. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol. 1995;153:117-120.
35. Schaeffer AJ. Review of norfloxacin in complicated and recurrent urinary tract infections. Eur Urol. 1990;17(suppl 1):19-23.
36. Ulmann A, Clavel J, Destree D, Dubois C, Mombet A, Brisset JM. Natural history of renal calcium lithiasis: data obtained from a cohort of 667 patients [in French]. Presse Med. 1991;20:499-502.
37. Pak CY. Nephrolithrasis. Curr Ther Endocrinol Metab. 1997;6:572-576.
38. Roberts JA. Management of pyelonephritis and upper urinary tract infections. Urol Clin North Am. 1999;26:753-763.
39. Eykyn SJ. Urinary tract infections in the elderly. Br J Urol. 1998;82(suppl 1):79-84.
40. Hamilton-Miller JM. Issues in urinary tract infections in the elderly. World J Urol. 1999;17:396-401.
41. Dewandre M, Franck J, Lecomte J, Mutsers A, Taziaux P. The hazards of bed rest in the elderly [in French]. Rev Med Liege. 1981;36:894-902.
42. Allen C, Glasziou P, Del Mar C. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet. 1999;354:1229-1233.
43. Proca E, Radulescu R, Calin C, Calomfirescu N, Nasaudean J, Natu A. Clinical comments on management of urosepsis in a general urological department. Acta Urol Belg. 1992;60:41-56.
44. Magee JT, Pritchard EL, Fitzgerald KA, Dunstan FD, Howard AJ. Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8. BMJ. 1999;319:1239-1240.
45. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A. 1999;96:1152-1156.
46. Pedersen G, Schonheyder HC, Steffensen FH, Sorensen HT. Risk of resistance related to antibiotic use before admission in patients with community-acquired bacteraemia. J Antimicrob Chemother. 1999;43:119-126.
47. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested casecontrol study with multivariate analysis for other risk factors. J Antimicrob Chemother. 2001;47:781-787.
48. Roberts JA, Domingue GJ, Martin LN, Kim JC, Rangan SR. Immunology of pyelonephritis in the primate model, II: effect on immunosuppression. Investig Urol (Berl). 1981;19:148-153.